Streetbeat News

ASND

Ascendis Pharma A/S

https://ascendispharma.com

Industry

Biotechnology

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapeutics for unmet medical needs. The company offers SKYTROFA for treating patients with growth hormone deficiency (GHD). It also develops TransCon Growth Hormone (hGH) for pediatric GHD in Japan; TransCon hGH for adults with GHD; TransCon parathyroid hormone for adult hypoparathyroidism; and TransCon CNP for pediatric achondroplasia. In addition, the company develops TransCon toll like receptors 7/8 agonist for intratumoral delivery; and TransCon IL-2 ß/g for systemic delivery. The company was incorporated in 2006 and is headquartered in Hellerup, Denmark.

Open

N/A

Mkt cap

N/A

Volume

N/A

High

N/A

P/E Ratio

N/A

52-wk high

N/A

Low

N/A

Div yield

N/A

52-wk low

N/A

JP Morgan analyst Jessica Fye maintains an Overweight rating on Ascendis Pharma and raises the price target from $170 to $174.

Portfolio Pulse from Benzinga Newsdesk

August 21, 2024 | 2:03 pm

Ascendis Pharma shares are trading higher following price target increases from Goldman Sachs and Jefferies.

Portfolio Pulse from Benzinga Newsdesk

August 13, 2024 | 7:03 pm

Jefferies analyst Kelly Shi maintains a Buy rating on Ascendis Pharma (NASDAQ:ASND) and raises the price target from $174 to $196.

Portfolio Pulse from Benzinga Newsdesk

August 13, 2024 | 5:27 pm

Loar Holdings Inc. (NYSE:LOAR) reported better-than-expected second-quarter earnings and sales, leading to an 18.2% increase in its stock price. Other notable gainers include iLearningEngines, Inc. (NASDAQ:AILE), Starbucks Corporation (NASDAQ:SBUX), PACS Group, Inc. (NYSE:PACS), Pulse Biosciences, Inc. (NASDAQ:PLSE), and Clean Energy Fuels Corp. (NASDAQ:CLNE), among others.

Portfolio Pulse from Avi Kapoor

August 13, 2024 | 3:44 pm

Goldman Sachs analyst Paul Choi maintains a Buy rating on Ascendis Pharma (NASDAQ:ASND) and raises the price target from $170 to $195.

Portfolio Pulse from Benzinga Newsdesk

August 13, 2024 | 1:27 pm

The FDA has approved Ascendis Pharma's (NASDAQ:ASND) Yorvipath (palopegteriparatide) for treating hypoparathyroidism in adults, making it the first and only treatment available after Takeda's (NYSE:TAK) Natpar/Natpara was discontinued due to supply issues. Ascendis plans to launch Yorvipath with patient services and anticipates initial supply availability in Q1 2025.

Portfolio Pulse from Vandana Singh

August 12, 2024 | 2:42 pm

Market-Moving News for August 12th includes Scotiabank's acquisition of a 14.9% stake in KeyCorp, Ascendia Pharma's FDA approval for YORVIPATH, and Deutsche Bank's upgrade of Eli Lilly's stock.

Portfolio Pulse from Benzinga Newsdesk

August 12, 2024 | 12:21 pm

Ascendia Pharma shares are trading higher following the FDA approval of YORVIPATH for treating hypoparathyroidism in adults.

Portfolio Pulse from Benzinga Newsdesk

August 12, 2024 | 12:13 pm

Trading for Ascendis Pharma (ASND) was halted and then resumed at 7:25 AM ET. The halt was due to pending news.

Portfolio Pulse from Benzinga Newsdesk

August 12, 2024 | 11:25 am

The FDA has approved Ascendis Pharma's Yorvipath (Palopegteriparatide; developed as TransCon PTH) for the treatment of hypoparathyroidism in adults. Ascendis is finalizing the manufacturing process for the U.S. market and expects the initial supply to be available in Q1 of 2025.

Portfolio Pulse from Benzinga Newsdesk

August 12, 2024 | 11:05 am

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.